Bedaquiline Fumarate and Pertuzumab Intravenous

• Generic Name: bedaquiline
• Dosage Forms: n.a.
• Other Brand Names: Sirturo

Treatment of pulmonary multidrug-resistant tuberculosis (i.e., caused by Mycobacterium tuberculosis resistant to isoniazid and rifampin) in conjunction with other antituberculosis agents.

Designated an orphan drug by FDA for use in treatment of active tuberculosis.

Use only when an effective treatment regimen for multidrug-resistant tuberculosis cannot otherwise be provided.

Safety and efficacy for treatment of drug-susceptible tuberculosis, extrapulmonary (e.g., CNS) tuberculosis, or latent tuberculosis infection not established; use not recommended.

Safety and efficacy for treatment of infections caused by nontuberculous mycobacteria (NTM) not established; use not recommended.

Patients with multidrug-resistant tuberculosis are at high risk for treatment failure and acquisition of further drug resistance. ATS, CDC, and IDSA recommend that such patients be referred to or that consultation be obtained from a specialized treatment center as identified by local or state health departments or the CDC.

• Generic Name: pertuzumab
• Dosage Forms: n.a.
• Other Brand Names: Perjeta

Pertuzumab injection is used to treat breast cancer that has spread to other parts of the body. It is used together with other cancer medicines (eg, docetaxel, trastuzumab) to treat patients with HER2-positive breast cancer. The HER2 protein is produced by some breast tumors. Pertuzumab is a monoclonal antibody that interferes with the growth of this protein, which is eventually destroyed by the body.

Pertuzumab is also used as part of a complete treatment regimen for early breast cancer before surgery and as an additional treatment for breast cancer that is at high risk for occurring again.

Pertuzumab is to be given only by or under the immediate supervision of your doctor.